1. Introduction In an important decision of February 8, 2022 the Brussels Dutch Court of Enterprises (hereafter the “Court of Enterprises”) declared null and void a patent on an “apparatus, system and method for filling containers with fluids” (hereafter the “patent in suit”). The decision is interesting for multiple reasons, but this article will only…

This is a follow-up to Jan-Diederik Lindemans’ post of 18 December 2019 discussing the guidelines on legal privilege during saisie-contrefaçon adopted by the Brussels Bar Association (‘BBA’) on 21 October 2019. In a judgment of 26 March 2020, the Ghent Business Court confirmed the BBA’s position on this issue. In the 26 March 2020 judgment,…

The Brussels Bar Association (Dutch speaking section, hereafter BBA) recently issues the third guideline since it was created in 1994. In this Guideline the BBA instructs its members how they should safeguard the attorney-client privilege in the event of a saisie contrefaçon at the client. Since the Brussels courts have exclusive competence for patent litigation…

Yesterday, 25 April 2018, AG Wathelet has handed down his opinion in the Teva v Gilead reference (Case C-121/17) suggesting that the question should be answered as follows: “The fact that a substance or combination of substances falls within the scope of protection of the basic patent is a necessary, but not sufficient, requirement for…

In last month’s blog about the recovery of legal costs in Belgian IP enforcement proceedings, it was announced that the Mons Court of Appeal would probably be the first Belgian court to hand down a substantive ruling on the consequences of United Video Properties / Telenet (CJEU of 28 July 2016, C-57/15). A week later,…

On May 9, 2017, the Dutch-speaking Brussels court of commerce handed down its decision on the merits in the context of an infringement action initiated by Orion and its exclusive licensee Novartis against Belgian generic company Eurogenerics. The proceedings relate to Orion’s European patent EP 1 189 608, concerning an oral three-in-one solid composition of…

On April 3, 2017, the latest decision was handed down in the patent revocation battle between medical device manufacturer Nouvag and Jean Malak, a plastic surgeon specialized in liposuction. This conflict has taken on epic proportions, in part because of the ruling rendered by the Belgian Supreme Court on February 3, 2012 confirming that the…

The UK IPO (the British bureau for intellectual property) recently made clear to various stakeholders that the proceedings for British approval of the agreement on a Unified Patent Court, better known as the “UPC Agreement”) continue. The UK IPO mentioned however that the UPC Agreement will probably be voted upon only after the British EU…

By Christian Dekoninck, Crowell & Moring The Brussels Court of Appeal has clarified in a recent decision that a judge, who has previously ruled on a preliminary injunction in a patent case, may be part of the court deciding on the merits relating to the same patent. The Court of Appeal held that there is no…

The European patent community and especially the people involved in the preparation of the Unified Patent Court were stirred up in March 2015 by an action launched before the Belgian Constitutional Court. On 10 March 2015 the Belgian non for profit association ESOMA (European Software Market Association) had launched a nullity action against the Belgian…